Cargando…

Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial

BACKGROUND: Based on non-clinical data, it is expected that azilsartan, an angiotensin II receptor blocker, will help improve insulin resistance in addition to its hypotensive action. The present study is aimed to explore the effect of azilsartan compared to telmisartan on insulin sensitivity in hyp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naruse, Mitsuhide, Koike, Yasuhiro, Kamei, Nozomu, Sakamoto, Ryuichi, Yambe, Yuko, Arimitsu, Michinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447197/ https://www.ncbi.nlm.nih.gov/pubmed/30943275 http://dx.doi.org/10.1371/journal.pone.0214727

Ejemplares similares

Efficacy and Safety of Azilsartan and Telmisartan in Hypertensive Patients
por: Kumar, Alok, et al.
Publicado: (2021)

Comparative Study of the Effects of Azilsartan and Telmisartan on Insulin Resistance and Metabolic Biomarkers in Essential Hypertension Associated With Type 2 Diabetes Mellitus
por: Meher, Bikash R, et al.
Publicado: (2022)

Efficacy and Safety of Azilsartan Medoxomil and Telmisartan in Hypertensive Patients: A Randomized, Assessor-Blinded Study
por: Garg, Megha, et al.
Publicado: (2020)

Comparison of Efficacy and Safety of Azilsartan and Amlodipine Combination Versus Telmisartan and Amlodipine Combination in Hypertensive Patients: A Non-inferiority Trial
por: Dash, Ashish, et al.
Publicado: (2023)

Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study
por: Handley, Alison, et al.
Publicado: (2016)

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
por: Juhasz, Attila, et al.
Publicado: (2018)

Azilsartan: Current Evidence and Perspectives in Management of Hypertension
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Effect of azilsartan versus candesartan on morning blood pressure surges in Japanese patients with essential hypertension
por: Rakugi, Hiromi, et al.
Publicado: (2014)

A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients with Essential Hypertension and Type 2 Diabetes in Asia
por: Deerochanawong, Chaicharn, et al.
Publicado: (2022)

Critical evaluation of the efficacy and tolerability of azilsartan
por: De Caterina, Alberto R, et al.
Publicado: (2012)

The Effect of Telmisartan on Endothelial Function and Arterial Stiffness in Patients With Essential Hypertension
por: Jung, An Doc, et al.
Publicado: (2009)

Clinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension
por: Shuster, Jerrica E, et al.
Publicado: (2012)

Open-label, Randomized Crossover Study Between Telmisartan and Valsartan on Improving Insulin Resistance and Adipocytokines in Nondiabetic Patients with Mild Hypertension
por: Ohbayashi, Hiroyuki, et al.
Publicado: (2010)

Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study
por: Ito, Shuichi, et al.
Publicado: (2021)

Improvement of Diurnal Blood Pressure Variation by Azilsartan
por: Okamura, Keisuke, et al.
Publicado: (2018)

Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension
por: Saha, Lekha
Publicado: (2011)

Metabolic effect of combined telmisartan and nifedipine CR therapy in patients with essential hypertension
por: Shimizu, Yuji, et al.
Publicado: (2012)

Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension
por: Akat, Pramod B., et al.
Publicado: (2010)

Effects of telmisartan on vascular endothelial function, inflammation and insulin resistance in patients with coronary heart disease and diabetes mellitus
por: Chen, Tao, et al.
Publicado: (2018)

Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy
por: Pushpakom, Sudeep P, et al.
Publicado: (2015)

Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension
por: Weber, Michael A., et al.
Publicado: (2014)

Correction to: Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study
por: Ito, Shuichi, et al.
Publicado: (2022)

Azilsartan/chlorthalidone combination therapy for blood pressure control
por: Cheng, Judy WM
Publicado: (2013)

Optimization, characterization and in vitro/vivo evaluation of azilsartan nanocrystals
por: Ma, Jingjing, et al.
Publicado: (2017)

Telmisartan and cardioprotection
por: Akhrass, Philippe R, et al.
Publicado: (2011)

Pharmacokinetics of a Single Dose of Azilsartan in Pediatric Patients: A Phase 3, Open-Label, Multicenter Study
por: Enya, Kazuaki, et al.
Publicado: (2018)

New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
por: Volpe, Massimo, et al.
Publicado: (2012)

Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy
por: Angeloni, Emiliano
Publicado: (2016)

Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro
por: Pushpakom, Sudeep P, et al.
Publicado: (2018)

A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension
por: Wu, Jiahui, et al.
Publicado: (2020)

Differential pharmacology and benefit/risk of azilsartan compared to other sartans
por: Kurtz, Theodore W, et al.
Publicado: (2012)

Crystal structure of azilsartan methyl ester ethyl acetate hemisolvate
por: Li, Zhengyi, et al.
Publicado: (2015)

SAT-545 Diabetes Mellitus Is the Risk Factor of Cardiovascular and Cerebrovascular Events in Primary Aldosteronism
por: Otsuki, Michio, et al.
Publicado: (2020)

A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension: Erratum
Publicado: (2020)

Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension
por: Johnson, Wallace, et al.
Publicado: (2017)

Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension
por: Iwashima, Yoshio, et al.
Publicado: (2023)

Comparison of Patient-Led and Physician-Led Insulin Titration in Japanese Type 2 Diabetes Mellitus Patients Based on Treatment Distress, Satisfaction, and Self-Efficacy: The COMMIT-Patient Study
por: Ishii, Hitoshi, et al.
Publicado: (2021)

Spectrophotometric and Spectrofluorimetric Studies on Azilsartan Medoxomil and Chlorthalidone to Be Utilized in Their Determination in Pharmaceuticals
por: Ebeid, Walid M, et al.
Publicado: (2014)

A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone
por: Weber, Michael A, et al.
Publicado: (2018)

Azilsartan as “Add-On” Treatment with Methotrexate Improves the Disease Activity of Rheumatoid Arthritis
por: Mahmood, Naza Mohammed Ali, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6ekfjs44aobft8jjrd98r3phav